Bevacizumab and platinum-based combinations for recurrent ovarian cancer: a randomised, open-label, phase 3 trial.
Pfisterer J, Shannon CM, Baumann K, Rau J, Harter P, Joly F, Sehouli J, Canzler U, Schmalfeldt B, Dean AP, Hein A, Zeimet AG, Hanker LC, Petit T, Marmé F, El-Balat A, Glasspool R, de Gregorio N, Mahner S, Meniawy TM, Park-Simon TW, Mouret-Reynier MA, Costan C, Meier W, Reinthaller A, Goh JC, L'Haridon T, Baron Hay S, Kommoss S, du Bois A, Kurtz JE; AGO-OVAR 2.21/ENGOT-ov 18 Investigators.
Lancet Oncol. 2020 May;21(5):699-709. doi: 10.1016/S1470-2045(20)30142-X. Epub 2020 Apr 16.
Ovarian remnant syndrome.
Magtibay PM, Magrina JF.
Clin Obstet Gynecol. 2006 Sep;49(3):526-34. doi: 10.1097/00003081-200609000-00012.
AMH and Its Clinical Implications.
Shrikhande L, Shrikhande B, Shrikhande A.
J Obstet Gynaecol India. 2020 Oct;70(5):337-341. doi: 10.1007/s13224-020-01362-0. Epub 2020 Aug 19.
The VCD Mouse Model of Menopause and Perimenopause for the Study of Sex Differences in Cardiovascular Disease and the Metabolic Syndrome.
Brooks HL, Pollow DP, Hoyer PB.
Physiology (Bethesda). 2016 Jul;31(4):250-7. doi: 10.1152/physiol.00057.2014.
Ovarian remnant syndrome.
Webb MJ.
Aust N Z J Obstet Gynaecol. 1989 Nov;29(4):433-5. doi: 10.1111/j.1479-828x.1989.tb01783.x.
Ovarian remnant syndrome.
Magtibay PM, Nyholm JL, Hernandez JL, Podratz KC.
Am J Obstet Gynecol. 2005 Dec;193(6):2062-6. doi: 10.1016/j.ajog.2005.07.067.
Ovarian residual syndrome.
Bukovsky I, Liftshitz Y, Langer R, Weinraub Z, Sadovsky G, Caspi E.
Surg Gynecol Obstet. 1988 Aug;167(2):132-4.
Residual ovarian syndrome: A case report with classic symptoms, imaging and pathology findings, and treatment.
Fu SC, Su HY.
Taiwan J Obstet Gynecol. 2018 Oct;57(5):753-754. doi: 10.1016/j.tjog.2018.08.027.
DICER1 Tumor Predisposition.
Schultz KAP, Stewart DR, Kamihara J, Bauer AJ, Merideth MA, Stratton P, Huryn LA, Harris AK, Doros L, Field A, Carr AG, Dehner LP, Messinger Y, Hill DA.
2014 Apr 24 [updated 2020 Apr 30]. In: Adam MP, Feldman J, Mirzaa GM, Pagon RA, Wallace SE, Amemiya A, editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993–2025.
Efficacy of maintenance olaparib plus bevacizumab according to clinical risk in patients with newly diagnosed, advanced ovarian cancer in the phase III PAOLA-1/ENGOT-ov25 trial.
Harter P, Mouret-Reynier MA, Pignata S, Cropet C, González-Martín A, Bogner G, Fujiwara K, Vergote I, Colombo N, Nøttrup TJ, Floquet A, El-Balat A, Scambia G, Guerra Alia EM, Fabbro M, Schmalfeldt B, Hardy-Bessard AC, Runnebaum I, Pujade-Lauraine E, Ray-Coquard I.
Gynecol Oncol. 2022 Feb;164(2):254-264. doi: 10.1016/j.ygyno.2021.12.016. Epub 2021 Dec 22.
